Skip to main content

Help improve GOV.UK Sign up to take part in user research (opens in a new tab)

Medicines, medical devices

Guidance and regulation

Skip to results
436 results sorted by Most viewed
  • How to register your medical devices with the MHRA for the markets in Great Britain and Northern Ireland.

  • How to get information including patient information leaflets (PILs), details on how the medicine can be used (SPCs) and scientific reports (PARs).

  • What you need to do to place a medical device on the Great Britain, Northern Ireland and European Union (EU) markets.

  • Guidance on the various types of modifications that can be made to a clinical trial approval.

  • How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.

  • Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.

  • Sets out medicines that cannot be exported from the UK or hoarded because they are needed for UK patients.

  • A guide to the legislation enabling drug services and others to supply take home naloxone without a prescription to save a life in an emergency.

  • Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.

  • Information on telecare monitoring systems and personal alarms that can help you stay safe and independent at home.

  • Comply with good manufacturing practice (GMP) and good distribution practice (GDP), and prepare for an inspection.

  • How to get access to MHRA submissions portals, how to use them, where to go for help.

  • How to contact the MHRA for specific services or enquiries.

  • Device qualification and classification of ambient voice technology-enabled products that are medical devices intended to be placed on the market, or put into service, in Great Britain.

  • An overview of the process to get a marketing authorisation (MA), including submitting, fast-tracking an application, naming your medicine and paying fees.

  • How to help patients and their families reduce the risks of harm from opioid medicines.

  • How to package medicines for sale and what information you must provide to consumers and healthcare professionals.

  • Guidance on labelling for medicinal products used in clinical trials.

  • The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.

  • How to apply for a clinical trial (prior to 28 April 2026) including eligibility, phases, model IMPDs, costs and how to make changes to your application.